GoodRx (NASDAQ:GDRX) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• GoodRx Holdings, Inc. experienced a significant rise in trading volume, with 2,451,815 shares traded, up 14% from the previous session, while the stock price fell to $4.55 from a prior close of $5.03.
• Analysts have mixed views on GoodRx, with Deutsche Bank maintaining a "hold" rating and a $6.00 price target, while Raymond James downgraded the stock from "strong-buy" to "outperform."
• In its latest quarterly earnings report, GoodRx missed earnings expectations with $0.09 per share against a consensus of $0.10, and reported a 1.2% year-over-year revenue growth despite lower than anticipated revenue.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares saw an uptick in trading volume on Thursday . 2,451,815 shares changed hands during mid-day trading, an increase of 14% from the previous session's volume of 2,157,990 shares.The stock last traded at $4.55 and had previously closed at $5.03.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GDRX. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial downgraded shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, GoodRx has an average rating of "Hold" and an average target price of $5.80.

GoodRx Stock Down 6.3%

The stock's 50-day moving average price is $4.27 and its 200-day moving average price is $4.39. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of 46.85, a P/E/G ratio of 1.84 and a beta of 1.23. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 EPS. On average, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently bought and sold shares of GDRX. Deutsche Bank AG purchased a new position in GoodRx during the 4th quarter worth $137,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of GoodRx by 70.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 149,945 shares of the company's stock worth $697,000 after buying an additional 61,924 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of GoodRx by 12.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 362,713 shares of the company's stock worth $1,600,000 after buying an additional 39,337 shares during the last quarter. CWA Asset Management Group LLC purchased a new position in shares of GoodRx in the 1st quarter worth about $292,000. Finally, Teacher Retirement System of Texas purchased a new stake in GoodRx during the first quarter valued at about $218,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.